Impact BioMedical, INC. Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset
Impact BioMedical, INC. (IBO) reported Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset of $782.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset · last filed 2023-11-13
- 2023-09-30: Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset 9 month $782.00K.
| Period end | Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset 9 month |
|---|---|
| 2023-09-30 | $782.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |